MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.

The a2 Milk Co. Ltd. engages in the distribution and sale of milk and dairy products. It operates through the following segments: Australia and New Zealand, China and Other Asia, & United Kingdom and USA. The Australia and New Zealand segment receives external revenue from infant formula, milk and dairy products, along with royalty and license fee income. The China and Other Asia segment includes exporting of infant formula, milk, and dairy products. The United Kingdom and USA segment focuses on milk, and infant formula sales. The company was founded by Corran McLachlan and Howard Paterson on February 17, 2000 and is headquartered in Auckland, New Zealand.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The company was founded by Christian Gurth Hoyer Millar, Alexandre Akoulitchev, and Aroul Ramadass on April 23, 2007 and is headquartered in Oxford, the United Kingdom.

Allele Biotechnology and Pharmaceuticals is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. It aims to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. It was founded in 1999 and is headquartered in San Diego, California.

Developer of a 3G sequencing technology using microscope. The company's platform technology addresses the major pain points in key areas of genomics research (what can be studied, the pace at which data can be understood, and the cost of discovery research) and thereby become a valued resource to the genomics industry, molecular diagnostics, and the future of personalized medicine.

Exact Sciences Development Co. LLC, part of EXACT Sciences Corp., is an American company. The firm engages in research and development diagnostic test for cancer.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

Zymo Research's core beliefs are based on innovation, quality, and customer service. These three paradigms are ingrained in their company culture. They believe their products are the most reliable and uphold to the highest standards of quality in the industry as evidenced by their ISO 9001 certification. They have also received Frost & Sullivan's Best Practices Award for Leadership in Epigenetics Product Quality.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Grail Ltd. develops blood-plasma tests to detect deadly diseases at their earliest stages when curative treatments are viable. The firm focuses on the early detection of cancer. The company was founded in Dennis Lo, Rossa Chiu, and Allen Chan in 2014 and is headquartered in Hong Kong.

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Apollo is a wellness product, the first clinically validated wearable that actively helps the body recover from stress. Apollo Neuroscience is a wellness product not intended to treat psychiatric disorders such as generalized anxiety disorder, social anxiety disorder, and panic disorder. Apollo is not a substitute for professional medical care.

Meio Technology (Guangzhou) Co., Ltd., established on 2019-05-13, Business scope includes engineering and technology research and experimental development;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Computer System Services;software development;Artificial intelligence basic software development;marketing planning;Corporate Image Planning;Conference and Exhibition Services;Advertising Design,acting;advertisement making;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);Human stem cell technology development and application;R&D and application of cell technology;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Medical Research and Experimental Development;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Sales of hygiene products and single-use medical products;Wholesale of protective equipment for medical staff;daily mask(non-medical)Sales;Wholesale medical masks;Remote Health Management Services;Health Consulting Services(Does not include medical services);data processing services;Data processing and storage support services;Natural science research and experimental development;Blockchain technology related software and services;Manufacturing of medical packaging materials;Production of Class I Medical Devices;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Import and export;Technology Import and Export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of hygiene products and single-use medical products;medical service;Inspection and testing service